MedTrace Logo

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

NCT01627132 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-06-25

No results posted yet for this study

Summary

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on dasatinib.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Dasatinib

100mg QD

Sponsors & Collaborators

  • Epidemiological and Clinical Research Information Network

    collaborator OTHER

  • Shimousa Hematology Study Group

    lead OTHER

Principal Investigators

  • Koiti Inokuchi · Nippon Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2017-02-28
Completion
2019-01-31

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01627132 on ClinicalTrials.gov